Abstract

Advances in liquid biopsy handling and processing have reinvigorated interest in ex vivo screening methods for drug discovery and as an emerging feature of patient care in the field of hematological cancers. Treatments based on ex vivo assays are gaining traction since they have demonstrated new benefits using approved drugs to treat leukemia and associated cancers. Various unique assay platforms, specifically designed to predict therapeutic response in leukemic patients within a clinically actionable time frame, have shown high accuracy, reproducibility and highthroughput potential and promise to serve as a decision support system for therapeutic management of multiple hematologic malignancies.

Keywords: Hematologic malignancy; Ex vivo tissue culture; Tumor microenvironment; Clinical therapy guidance; AML